Regeneron Pharmaceuticals Financial Indicators Patterns

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

We recommend to use Regeneron Pharmaceuticals fundamental analysis to see if markets are presently mispricing the firm. Put it differently this interface allows you to confirm available drivers of Regeneron Pharmaceuticals as well as the relationship between them. We found thirty-six available financial ratios for Regeneron Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check all Regeneron Pharmaceuticals fundamentals including its Debt to Equity, Total Asset and the relationship between EBITDA and Earnings Per Share . Given that Regeneron Pharmaceuticals has Number of Shares Shorted of 2.48 M, we recommend you check out Regeneron Pharmaceuticals recent market performance to make sure the company can sustain itself down the road. Use Regeneron Pharmaceuticals to enhance returns of your portfolios. The stock experiences very speculative upward sentiment. . Check odds of Regeneron Pharmaceuticals to be traded at $448.92 in 30 days.

Chance of Financial Distress

Regeneron Pharmaceuticals has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Regeneron Pharmaceuticals Company Summary

Regeneron Pharmaceuticals competes with Vertex Pharmaceuticals, Dr Reddys, Zoetis, Perrigo Company, and Regeneron Pharmaceuticals. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.
Foreign Associates
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
ExchangeBATS Exchange
CIK Number0000872589
RegionNorth America
Business Address777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
Phone914 847 7000
CurrencyUSD - US Dollar

Regeneron Pharmaceuticals Key Fundamentals

Regeneron Pharmaceuticals Current Ratio vs Z Score

Regeneron Pharmaceuticals is rated third in current ratio category among related companies. It is rated third in z score category among related companies totaling about  8.73  of Z Score per Current Ratio.

Regeneron Pharmaceuticals Systematic Risk

The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Regeneron Pharmaceuticals correlated with the market. If Beta is less than 0 Regeneron Pharmaceuticals generally moves in the opposite direction as compared to the market. If Regeneron Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regeneron Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regeneron Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Regeneron Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Regeneron Pharmaceuticals Thematic Clasifications

Cancer Fighters Idea
Cancer FightersView
Biotech Idea

Regeneron Pharmaceuticals January 25, 2020 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Company logos by clearbit